Curis, Inc. (CRIS) Announces Presentation of CUDC-427 and Erivedge® Clinical Results at American Society of Clinical Oncology Annual Meeting
5/16/2013 9:24:25 AM
More...
|
Curis, Inc. (CRIS) Announces Approval of Erivedge® in Australia
5/10/2013 9:36:21 AM
More...
|
Curis, Inc. (CRIS) Announces Erivedge® Receives Positive CHMP Opinion for Conditional Approval in European Union
4/26/2013 11:39:52 AM
More...
|
Curis, Inc. (CRIS) to Present at the Needham 12th Annual Healthcare Conference
4/24/2013 12:49:11 PM
More...
|
Curis, Inc. (CRIS) Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907
1/24/2013 9:25:01 AM
More...
|
Curis, Inc. (CRIS) Announces Closing of $30 Million Secured Debt Financing
12/12/2012 6:54:58 AM
More...
|
Curis, Inc. (CRIS) Announces $30 Million Secured Debt Financing
11/28/2012 6:47:51 AM
More...
|
Curis, Inc. (CRIS) Reports Third Quarter 2012 Financial Results
11/6/2012 9:34:17 AM
More...
|
Curis, Inc. (CRIS) to Release Third Quarter 2012 Financial Results and Hold Conference Call on November 6, 2012
10/30/2012 6:51:36 AM
More...
|
Curis, Inc. (CRIS) Achieves CUDC-907 Milestones Under Its Agreement With The Leukemia & Lymphoma Society
10/18/2012 9:12:43 AM
More...
|
|